| Name | Title | Contact Details |
|---|
GO ARMY I BEAT NAVY! The U.S. Military Academy competes as ARMY WEST POINT in a broad range of NCAA D-1 and D-2 sports. At West Point, its all fun and games for ARMY fans, but every cadet on the field or court understands that competition through their sport is a critical component for developing their leadership and teamwork skills, and especially for building personal bonds. West Points competitive sports programs support the Army values of loyalty, duty, respect, selfless service, honor, integrity, and personal courage. It is designed to teach these values in an athletic setting. The nature of competitive sports provides opportunities that are difficult to replicate in the conventional classroom, in other extracurricular activities, or in military field training.
Le groupe international Ondura est spécialisé dans les solutions détanchéité pour les bâtiments et regroupe des entreprises leaders dans leurs domaines : Onduline (toiture légère pour les toits en pente), CB (écrans de protection pour façades et de sous-toiture pour toits inclinés) et Alwitra (systèmes détanchéité hautes performances pour les toits plats). Il dispose de 13 usines en France, Allemagne, Pologne, Espagne, Russie, États-Unis, Malaisie, Brésil et Turquie. Il réalise un chiffre daffaires consolidé de 350 M€ dans plus de 100 pays et emploie 2000 personnes de 34 nationalités différentes.
Invisible is the operations innovation company transforming how companies are built and run. Our tech-enabled service harnesses our proprietary process orchestration platform, which seamlessly blends AI and automation with a global team of over 2000 highly-skilled agents. This integration eliminates execution bottlenecks and opens up new efficiency, scale, and growth possibilities for clients, delivering any operations capability better, faster, and cheaper than traditional 20th century services companies.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
If youre looking to have your team transform into a community like never before and solve an eroding culture or the crisis of Disconnection, were the place for that. Were turning isolation into Connection through "The Other 89 Days"